Alzamend Neuro Files 8-K on Equity Sales
Ticker: ALZN · Form: 8-K · Filed: Aug 1, 2025 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | 8-K |
| Filed Date | Aug 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, filing
TL;DR
Alzamend Neuro sold unregistered equity, check for dilution.
AI Summary
Alzamend Neuro, Inc. filed an 8-K on August 1, 2025, reporting unregistered sales of equity securities. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Atlanta, Georgia.
Why It Matters
This filing indicates potential dilution for existing shareholders due to the unregistered sale of equity securities. Investors should monitor future filings for details on the terms and impact of these sales.
Risk Assessment
Risk Level: medium — Unregistered sales of equity can lead to dilution and may involve securities sold under exemptions that could have future implications.
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- August 1, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Atlanta, GA (location) — Principal executive offices
FAQ
What specific item is being reported under the 'Unregistered Sales of Equity Securities' section?
The filing indicates 'Unregistered Sales of Equity Securities' as an item being reported, but the specific details of the sale are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 1, 2025.
In which state is Alzamend Neuro, Inc. incorporated?
Alzamend Neuro, Inc. is incorporated in Delaware.
What is the business address of Alzamend Neuro, Inc.?
The business address of Alzamend Neuro, Inc. is 3500 Lenox Rd. NE, Suite 1500, Atlanta, GA 30326.
What is the SIC code for Alzamend Neuro, Inc.?
The Standard Industrial Classification (SIC) code for Alzamend Neuro, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 1, 2025 regarding Alzamend Neuro, Inc. (ALZN).